The postMONARCH trial is a Phase 3, randomized, placebo-controlled study evaluating abemaciclib (Verzenio®) in combination with fulvestrant in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer who experienced disease progression following prior CDK4/6 inhibitor therapy. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and clinical benefit rate (CBR). The study demonstrated a statistically significant improvement in PFS for patients receiving abemaciclib plus fulvestrant compared to those receiving placebo plus fulvestrant. The safety profile of abemaciclib remained consistent with prior studies, with no new safety signals reported. Results were presented at the 2024 ASCO Annual Meeting and highlighted by leading oncology experts including Dr. Kevin Kalinsky, Dr. Stephanie Graff, and Dr. Hope Rugo. For in-depth interpretation and clinical context, their commentary via social media offers valuable insights.
